- Home
- BDJ vs CLDX Comparison
BDJ vs CLDX Comparison
Compare BDJ & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDJ
- CLDX
- Stock Information
- Founded
- BDJ 2005
- CLDX N/A
- Country
- BDJ United States
- CLDX United States
- Employees
- BDJ N/A
- CLDX N/A
- Industry
- BDJ Finance Companies
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BDJ Finance
- CLDX Health Care
- Exchange
- BDJ Nasdaq
- CLDX Nasdaq
- Market Cap
- BDJ 1.6B
- CLDX 1.6B
- IPO Year
- BDJ N/A
- CLDX 2008
- Fundamental
- Price
- BDJ $9.00
- CLDX $27.59
- Analyst Decision
- BDJ
- CLDX Buy
- Analyst Count
- BDJ 0
- CLDX 9
- Target Price
- BDJ N/A
- CLDX $43.78
- AVG Volume (30 Days)
- BDJ 561.6K
- CLDX 958.4K
- Earning Date
- BDJ 01-01-0001
- CLDX 11-05-2025
- Dividend Yield
- BDJ 8.85%
- CLDX N/A
- EPS Growth
- BDJ N/A
- CLDX N/A
- EPS
- BDJ N/A
- CLDX N/A
- Revenue
- BDJ N/A
- CLDX $5,790,000.00
- Revenue This Year
- BDJ N/A
- CLDX N/A
- Revenue Next Year
- BDJ N/A
- CLDX N/A
- P/E Ratio
- BDJ N/A
- CLDX N/A
- Revenue Growth
- BDJ N/A
- CLDX N/A
- 52 Week Low
- BDJ $6.91
- CLDX $14.40
- 52 Week High
- BDJ $8.66
- CLDX $29.93
- Technical
- Relative Strength Index (RSI)
- BDJ 46.83
- CLDX 60.64
- Support Level
- BDJ $8.94
- CLDX $26.03
- Resistance Level
- BDJ $9.20
- CLDX $27.87
- Average True Range (ATR)
- BDJ 0.12
- CLDX 1.20
- MACD
- BDJ -0.02
- CLDX -0.05
- Stochastic Oscillator
- BDJ 25.37
- CLDX 89.26
About BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.